Mayo Clinic

Bi-allelic variants in CELSR3 are implicated in central nervous system and urinary tract anomalies (2024) Stegmann JD, Kalanithy JC, Dworschak GC, Ishorst N, Mingardo E, Lopes FM, Ho YM, et al. Journal article MARK2 variants cause autism spectrum disorder via the downregulation of WNT/β-catenin signaling pathway (2024) Gong M, Li J, Qin Z, Machado Bressan Wilke MV, Liu Y, Li Q, Liu H, et al. Journal article Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)] (2024) de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, et al. Journal article A brave new framework for glioma drug development (2024) Hotchkiss KM, Karschnia P, Schreck KC, Geurts M, Cloughesy TF, Huse J, Duke ES, et al. Journal article, Review article Xanthogranulomatous epithelial tumors/keratin-positive giant cell–rich tumors involving the head and neck: report of seven cases and review of the literature (2024) Whaley RD, Agaimy A, Bridge JA, Stöhr R, Din NU, Gagan J, Rampisela D, et al. Journal article Letter to the Editor: Announcement of a Call for Proposals for biomedical waveform coding (2024) Halford JJ, Campobello G, Brinkmann BH, Stead M, Rampp S, Rémi J, Nilsen KB, et al. Journal article PLAG1-Rearranged Uterine Sarcomas: A Study of 11 Cases Showing a Wide Phenotypical Spectrum Not Limited to Myxoid Leiomyosarcoma-like Morphology (2024) Michal M, Agaimy A, Croce S, Mechtersheimer G, Gross JM, Xing D, Bell DA, et al. Journal article Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma (2024) Saner FA, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer TA, Meagher NS, et al. Journal article The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD (2024) DeFilipp Z, Kim HT, Spyrou N, Katsivelos N, Kowalyk S, Eng G, Kasikis S, et al. Journal article 177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study (2024) Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel ME, Kunz PL, Chasen B, et al. Journal article